Recurrent Toxic Epidermal Necrolysis Syndrome: A Report of Two Cases

García Duval I, Roujeau JC, Cruces Prado MJ. Toxic epidermal necrolysis and Stevens-Johnson syndrome: classification and current therapeutics. Actas Dermosifiliogr. 2000;91:541–51.

Daubeney PEF, Scopes JW. Recurrent Stevens–Johnson syndrome. J R Soc Med. 1991;84:168.

Brown M, Yowler C, Brandt C. Recurrent toxic epidermal necrolysis secondary to Iopromide contrast. J Burn Care Res. 2013;34:e53–6.

Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, Chang HH, Lee JM, Kim NS. Korean J Intern Med. 2012;27:203–10.

Casselman J, Venglarcik J, Bludorn M 3rd, Chernin L, Swender D, Tcheurekjian H, Hostoffer R. Association of natural killer cell dysfunction and Stevens-Johnson syndrome in a pediatric patient. Allergy Rhinol. 2013;4(1):e25–6.

Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, Shear NH, Koren G, Shannon MW, Garcia-Bournissen F. Recurrence and outcomes of Stevens–Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128:723–8.

Pichler WJ. The p–i concept: Pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008;1(6):96–102.

Lim SK, Kwan P, Tin Tan C. Association of the HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reactions among Asians, a review. Neurol Asia. 2008;13:15–21.

Orellana BM, Guajardo TV. Cytochrome P450 activity and its alteration in various pathologies. Rev Méd Chile. 2004;132:85–94.

Chelo-Nuñez H. Cytochrome P450 and its role in drug-induced hepatotoxicity. Enf Ap Dig. 1999;2:34–7.

Hartel C, Entenmann A, Wygold T. Recurrent Stevens Johnson syndrome in winter. Pediatr Dermatol. 2004;21(3):282.

Campagna C, Tassinari D, Bernardij NF. Mycoplasma pneumoniae induced recurrent Stevens–Johnson syndrome in a children: a case report. Pediatr Dermatol. 2013;3(5):624–6.